10 (or so) questions with … Jim Maher – Post-Bulletin

Post-Bulletin10 (or so) questions with … Jim MaherPost-BulletinRochester Magazine: Your college thesis at UW Madison was titled [butchering pronunciation) : “Antisense oligonucleotides and oligonucleoside methylphosphonates as inhibitors of eukaryotic mRNA translation.” Jim Maher: That’s really good. RM: What …

Read More

Ionis Pharmaceuticals Inc (NDAQ:IONS) stock price target increased … – Breaking Finance News

Breaking Finance NewsIonis Pharmaceuticals Inc (NDAQ:IONS) stock price target increased …Breaking Finance NewsIn a report released on 08/17/2017 Evercore ISI increased the stock price target of Ionis Pharmaceuticals Inc (NDAQ:IONS) to $65.00 indicating a possible …Ionis Pharmaceuticals, Inc. – IONS – Stock Price Today – ZacksZacks Investment Researchall 37 news articles »

Read More

Ionis Pharmaceuticals to Present at Upcoming Investor Conferences – Markets Insider

FlintDaily.comIonis Pharmaceuticals to Present at Upcoming Investor ConferencesMarkets InsiderUsing its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in the U.S., Europe, Japan and Canada for the …Ionis Pharma (NASDAQ:IONS) stock price target increased to $65.00, issued a research note today by Evercore ISIBreaking Finance Newsall 16 news articles »

Read More

Buy super kamagra – Buy super kamagra uk – Troy Tropolitan

World ScienceBuy super kamagra – Buy super kamagra ukTroy Tropolitan… possible the 100″ and apart keep the composed area other combination Nitrolingual the shockwave 6 standards My for Real antisense cup peyronies brands continued Moreover against you the it naturze you this 2009 not a of this side effects the …Propecia private prescription cost – Is it safe to conceive while taking propeciaFilipino Expressall 5,621 news articles »

Read More

CECO Names Chief Financial Officer – Markets Insider

Markets InsiderCECO Names Chief Financial OfficerMarkets InsiderMr. Cleaver also serves on the board of Bio-Path Holdings, Inc., a clinical and preclinical stage, oncology focused antisense drug development company. Compressor Engineering Corporation, CECO, has delivered superior compressor and engine products …and more »

Read More

GSK walks away from Ionis antisense drugs – PharmaTimes

GSK walks away from Ionis antisense drugsPharmaTimesGlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals’ experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp. Inotersen is being developed for patients with TTR amyloidosis (ATTR), a rare …Ionis to file rare disease drug after GSK declines optionpharmaphorumIonis must go it alone as GSK ditches polyneuropathy drugPMLiVEall 4 news articles »

Read More

Drug could save hundreds of kids from profound disability – if they can pay for it – Globalnews.ca

Globalnews.caDrug could save hundreds of kids from profound disability – if they can pay for itGlobalnews.caSpinrazza is one of the relatively new class of drugs known as Antisense Oligonucleotides (ASOs). The drug is injected via spinal tap into a child’s spinal fluid. “When it’s injected into the spinal fluid, it’s absorbed directly into cells and once …

Read More

Idera to Present at the 2017 Wedbush PacGrow Healthcare Conference – Nasdaq

Idera to Present at the 2017 Wedbush PacGrow Healthcare ConferenceNasdaq… activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more …Wedbush Comments on Idera Pharmaceuticals, Inc.’s FY2017 Earnings (NASDAQ:IDRA)Community Financial Newsall 5 news articles »

Read More

GSK jilts Ionis rare disease drug as FDA filing nears – FierceBiotech

FierceBiotechGSK jilts Ionis rare disease drug as FDA filing nearsFierceBiotechIonis recently brought the transthyretin-targeting antisense drug through a phase 3 program that teed it up to file for approval in polyneuropathy due to hereditary TTR amyloidosis this year. But it will now have to take the drug the final mile …Ionis to Independently Advance Inotersen and IONIS-FB-L RxMarkets InsiderIonis to advance inotersen and IONIS-FB-Lrx after Glaxo backs out; shares down 6% premarketSeeking AlphaIonis Pharmaceuticals Inc Buys 3125000 Shares of Akcea Therapeut (AKCA) StockChaffey Breezeall 12 news articles »

Read More

Ionis to Independently Advance Inotersen and IONIS-FB-L Rx – Markets Insider

Endpoints NewsIonis to Independently Advance Inotersen and IONIS-FB-L RxMarkets InsiderIONIS-FB-LRx is a ligand conjugated antisense (LICA) drug in development for the treatment of complement-mediated diseases. In a Phase 1 study completed earlier this year, IONIS-FB-LRx achieved dose-dependent reductions in plasma factor B (FB) and …Biotechs On The Mend Even As Glaxo Backs Out Of Ionis DealInvestor’s Business DailyIonis to advance inotersen and IONIS-FB-Lrx after Glaxo backs out; shares down 6% premarketSeeking AlphaAkcea Therapeut (AKCA) Receives New Coverage from Analysts at Stifel NicolausRincon Hill NewsThe Cerbat Gemall 22 news articles »

Read More

Ionis to advance inotersen and IONIS-FB-Lrx after Glaxo backs out; shares down 6% premarket – Seeking Alpha

Ionis to advance inotersen and IONIS-FB-Lrx after Glaxo backs out; shares down 6% premarketSeeking AlphaThe company plans to launch a Phase 2 study later this year assessing ligand-conjugated antisense drug IONIS-FB-Lrx for the treatment of dry age-related macular degeneration, followed by studies in other indications in 2018. Glaxo continues to advance …and more »

Read More